Expression of cancer-testis antigen SPANXB and its mechanism in affecting hepatocellular carcinoma progress

doi:10.3969/j.issn.1674-8115.2024.07.001

Abstract

Abstract:

Objective ·To analyze the expression of cancer-testis antigen (CTA) family member SPANXB (sperm protein associated with the nucleus on the X chromosome B) in liver cancer and its correlation with the prognosis of liver cancer patients, and to explore the impact of SPANXB on liver cancer cell proliferation and its potential mechanism. Methods ·By using liver cancer sample data from the cancer genome atlas (TCGA) database, the expression of SPANXB in liver cancer tissue and its correlation with patient survival were analyzed. By constructing stable knockdown of SPANXB and stable overexpression of SPANXB in liver cancer cell lines, the effects of SPANXB on liver cancer cell proliferation were evaluated with live cell imaging experiments, EdU cell proliferation experiments and plate clone formation experiments. The regulatory pathways of SPANXB in liver cancer cell proliferation were explored through RNA-sequence (RNA-seq), and the effect of SPANXB on liver cancer cell cycle was validated through cell cycle experiments. Immunoprecipitation-mass spectrometry (IP-MS) was used to explore the proteins that interacted with SPANXB, and co-immunoprecipitation (Co-IP) was used to verify their interaction. Results ·The expression of SPANXB mRNA in liver cancer tissues was higher than that in normal tissues (P=0.003), and was negatively correlated with the survival of liver cancer patients. Stable knockdown of SPANXB could reduce the proliferation and clone formation ability of liver cancer cells, while stable overexpression of SPANXB could promote these processes. The analysis results of RNA-seq showed that knockdown of SPANXB could lead to downregulation of DNA replication and G1/S cell cycle transition-related pathways. The results of cell cycle experiments showed that knockdown of SPANXB could result in changes in the liver cancer cell cycle. The results of IP-MS and Co-IP showed that SPAXNB interacted with cell cycle-related proteins such as mitotic arrest defect 2-like protein 1 (MAD2L1) and WD repeat domain 5 (WDR5). Conclusion ·The high expression of SPANXB is negatively correlated with the prognosis of liver cancer. SPANXB may regulate the cell cycle and enhance the proliferation activity of liver cancer cells by interacting with MAD2L1 and WDR5.

Key words: cancer-testis antigen (CTA), sperm protein associated with the nucleus on the X chromosome B (SPANXB), liver cancer, cell cycle

CLC Number:

R735.7

XUE Yu, ZHANG Hailong, LEI Ming. Expression of cancer-testis antigen SPANXB and its mechanism in affecting hepatocellular carcinoma progress[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 801-813.

Figures/Tables 5

Fig 1 Analysis of SPANXB mRNA expression in pan-cancer and its correlation with OS in LIHC patients

Fig 2 Expression of SPANXB in hepatocellular carcinoma cell lines and effect of SPANXB knockdown on HepG2 cell proliferation phenotype

Fig 3 Overexpression of the SPANXB in Huh7 cells and its effects on cell proliferation phenotype

Fig 4 Analysis of SPANXB expression in relation to cell proliferation pathways and its impact on cell cycle

Fig 5 Analysis and validation of interaction proteins in SPANXB-overexpressed cells

TrendMD

References 32

1	SCANLAN M J, GURE A O, JUNGBLUTH A A, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy[J]. Immunol Rev, 2002, 188: 22-32.
2	PINEDA C T, RAMANATHAN S, FON TACER K, et al. Degradation of AMPK by a cancer-specific ubiquitin ligase[J]. Cell, 2015, 160(4): 715-728.
3	LI F, ZHAO F S, LI M, et al. Decreasing New York esophageal squamous cell carcinoma 1 expression inhibits multiple myeloma growth and osteolytic lesions[J]. J Cell Physiol, 2020, 235(3): 2183-2194.
4	GREVE K B, LINDGREEN J N, TERP M G, et al. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability[J]. Mol Oncol, 2015, 9(2): 437-449.
5	MIZUSHIMA E, TSUKAHARA T, EMORI M, et al. Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B[J]. Cancer Sci, 2020, 111(1): 36-46.
6	ZENDMAN A J, CORNELISSEN I M, WEIDLE U H, et al. CTp11, a novel member of the family of human cancer/testis antigens[J]. Cancer Res, 1999, 59(24): 6223-6229.
7	HSIAO Y J, SU K Y, HSU Y C, et al. SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma[J]. Oncotarget, 2016, 7(28): 44417-44429.
8	WANG X W, JU S H, CHEN Y, et al. Hypomethylation-activated cancer-testis gene SPANXC promotes cell metastasis in lung adenocarcinoma[J]. J Cell Mol Med, 2019, 23(11): 7261-7267.
9	ZHU F, BO H, LIU G M, et al. SPANXN2 functions a cell migration inhibitor in testicular germ cell tumor cells[J]. PeerJ, 2020, 8: e9358.
10	MAINE E A, WESTCOTT J M, PRECHTL A M, et al. The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion[J]. Oncotarget, 2016, 7(12): 14708-14726.
11	LAZAR I, FABRE B, FENG Y M, et al. SPANX control of lamin A/C modulates nuclear architecture and promotes melanoma growth[J]. Mol Cancer Res, 2020, 18(10): 1560-1573.
12	ALMANZAR G, OLKHANUD P B, BODOGAI M, et al. Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4⁺ and CD8⁺ T cells[J]. Clin Cancer Res, 2009, 15(6): 1954-1963.
13	PETRICK J L, FLORIO A A, ZNAOR A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012[J]. Int J Cancer, 2020, 147(2): 317-330.
14	FRACANZANI A L, CONTE D, FRAQUELLI M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease[J]. Hepatology, 2001, 33(3): 647-651.
15	LLOVET J M, KELLEY R K, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
16	ZUCMAN-ROSSI J, VILLANUEVA A, NAULT J C, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239.e4.
17	CHIANG D Y, VILLANUEVA A, HOSHIDA Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma[J]. Cancer Res, 2008, 68(16): 6779-6788.
18	HÄNZELMANN S, CASTELO R, GUINNEY J. GSVA: gene set variation analysis for microarray and RNA-seq data[J]. BMC Bioinformatics, 2013, 14: 7.
19	RITCHIE M E, PHIPSON B, WU D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47.
20	WU T, HU E, XU S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data[J]. Innovation (Camb), 2021, 2(3): 100141.
21	ZHANG X F, SMITS A H, VAN TILBURG G B, et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS[J]. Nat Protoc, 2018, 13(3): 530-550.
22	DAS B, SENAPATI S. Immunological and functional aspects of MAGEA3 cancer/testis antigen[J]. Adv Protein Chem Struct Biol, 2021, 125: 121-147.
23	YUASA T, OKAMOTO K, KAWAKAMI T, et al. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue[J]. J Urol, 2001, 165(5): 1790-1794.
24	HIROHASHI Y, TORIGOE T, TSUKAHARA T, et al. Immune responses to human cancer stem-like cells/cancer-initiating cells[J]. Cancer Sci, 2016, 107(1): 12-17.
25	HYMAN D M, TAYLOR B S, BASELGA J. Implementing genome-driven oncology[J]. Cell, 2017, 168(4): 584-599.
26	LIU S Z, MIAO M S, KANG L. Upregulation of MAD2L1 mediated by ncRNA axis is associated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma: a review[J]. Medicine (Baltimore), 2023, 102(2): e32625.
27	LI Q, TONG D D, JING X T, et al. MAD2L1 is transcriptionally regulated by TEAD4 and promotes cell proliferation and migration in colorectal cancer[J]. Cancer Gene Ther, 2023, 30(5): 727-737.
28	JIANG W J, YANG X, SHI K H, et al. MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex[J]. Oncogene, 2023, 42(45): 3344-3357.
29	WANG L, GUO B, WANG R W, et al. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib[J]. Clin Sci (Lond), 2012, 122(1): 13-24.
30	JIANG H. The complex activities of the SET1/MLL complex core subunits in development and disease[J]. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(7): 194560.
31	CHEN X, XIE W B, GU P, et al. Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation[J]. Sci Rep, 2015, 5: 8293.
32	ZHANG J T, ZHOU Q H, XIE K J, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 203.

[1]	HAN Yishan, XU Ziqi, TAO Mengyu, FAN Guangjian, YU Bo. PRMT6 promotes the proliferation and migration of breast cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(8): 999-1010.
[2]	WANG Wei, WANG Hongli, ALIBIYATI·i Ain, YILIYAER· Rousu, AYI NUER, YANG Liang. Function of vasohibin-2 and the mechanism of alternative splicing in triple-negative breast cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(12): 1526-1535.
[3]	LUO Lange, ZHENG Chao, LEI Ming. Promotive effect of cancer-testis antigen CT57 on proliferation, invasion, migration and epithelial-mesenchymal transition of liver cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(11): 1335-1346.
[4]	ZHANG Yin, WU Xian, XIE Bingluan, WANG Yi. Experience of laparoscopic ultrasound-guided ablation of diaphragmatic liver tumors [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 391-396.
[5]	WANG Lanxi, MA Guanrong, JIANG Yongzhu, CHANG Xiulin, FANG Liaoqiong, BAI Jin. Effects of Escherichia coli outer membrane vesicles on proliferation of breast cancer cells and tumor growth of tumor-bearing mice [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1245-1254.
[6]	ZONG Chunyan, HE Jie, ZHANG Zhe, JIA Renbing, SHEN Jianfeng. Role of APOBEC3B in regulating replication stress of uveal melanoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1034-1044.
[7]	XU Feixiang, WANG Sheng, XUE Mingming, TONG Chaoyang, CHEN Yumei. Effect of altered expression of long non-coding RNA-B230352I09 on proliferation and cycle of H9C2 cardiomyocytes [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(5): 578-582.
[8]	Wei HE, Yong ZUO. Effect of oridonin up-regulating PLK1 on the cell cycle of Jurkat cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 603-611.
[9]	HE Ming, WEI Qian, ZHANG Ying-ting. Research progress in the mechanism of ferroptosis and its role in liver related diseases [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1519-1523.
[10]	GU Xiao-ping1, CHEN Meng-ping1, LIANG A-juan2, LIU Yun-xia1, SUN Hai-peng1, HUANG Ying1. Regulation of mitochondrial carrier SLC25A13 on breast cancer cell cycle in vitro [J]. , 2019, 39(8): 848-.
[11]	WANG Jia-lin, JI Di, CHEN Xiang, YANG Bo, YU Lin. Effect of miR-218-2-3P on proliferation and apoptosis of NK/T-cell lymphomatargeting SIN3A [J]. , 2019, 39(12): 1394-.
[12]	DI Fang-fang, LIU Jian-sheng, LI Shang, DU Yan-zhi . Progress on roles and mechanisms of CCAAT/enhancer binding protein β in endometrium decidualization [J]. , 2017, 37(6): 865-.
[13]	WEI Ying-qing, ZHANG Lu, HU Yu-tong, ZHANG Jian, SHEN Ying . Novel small-molecule CDK2-cyclinA2 inhibitors: design, synthesis, and biological evaluation [J]. , 2017, 37(3): 330-.
[14]	SHAO Yuan-yuan, ZHANG Lu, SHEN Ying, ZHANG Jian. Virtual screening of and in vitro activity study on allosteric small-molecule CDK2 inhibitors [J]. , 2016, 36(4): 523-.
[15]	FENG Jing, DENG Fei, ZHANG Ping, et al. Influence of Venenum Bufonis on proliferation and apoptosis in liver cancer cell HepG2 and relevant mechanisms [J]. , 2016, 36(3): 340-.